Health Care Provider Fact Sheet

Disease Name Methylmalonic acidemia, Vitamin B-12 responsive

Alternate name(s) Methylmalonic acidemia, Vitamin B-12 responsive, due to defect in

adenosylcobalamin, cblA complementation type; Methylmalonic acidemia, cblA type; Methylmalonic acidemia, Vitamin B-12 responsive, due to defect in

synthesis of adenosylcobalamin, cbl B complementation type

Acronym MMA, MMAA/MMAB

Disease Classification Organic Acid Disorder

Variants Yes

Variant name Methylmalonic acidemia, Vitamin B-12 non-responsive; Combined deficiency of

methylmalonyl-CoA mutase and homocysteine

Symptom onset Variable. Ranges from the first days of life to completely asymptomatic.

Symptoms Episodic ketoacidosis with vomiting accompanied by lethargy and coma which can lead to death. Survivors can have developmental delays, growth retardation,

can lead to death. Survivors can have developmental delays, growth retardation spastic quadriparesis, dystonia and seizures. Neutropenia, thrombocytopenia

and osteoporosis are common complications.

Natural history without treatment Variable depending on the enzyme defect. Some will die in the newborn period,

others will survive with deficits and others will be asymptomatic.

Natural history with treatment CbIA: Good prognosis with injections of hydroxy-cobalamin (OH-cbl) which reverses biochemical and clinical abnormalities in about 90% of patients.

CbIB: Equal fractions of affected patients are alive and well, alive and impaired, or deceased. The age of onset of symptoms can help prognosticate outcome – those patients with a later onset of symptoms have a more benign course.

Approximately 40% of patients will respond with a drop in MMA level when given

OH-cbl injections.

Treatment Protein restricted diet, OH-cbl injections, carnitine supplementation, oral

antibiotic therapy to decrease proprionate and medical foods. Liver transplant or combined liver/kidney transplant may increase metabolic control, but may not

prevent neurologic complications.

Emergency Medical Treatment See sheet from American College of Medical Genetics (attached) or for more

information, go to website: http://www.acmg.net/StaticContent/ACT/C3.pdf

Physical phenotype Minor facial dysmorphisms including high forehead, broad nasal bridge,

epicanthal folds, long, smooth philtrum and triangular mouth. A variety of skin

lesions can be seen in patients due to moniliasis.

Inheritance Autosomal recessive

General population incidence 1:48,000

Ethnic differences No known population at increased risk

Population N/A
Ethnic incidence N/A

Enzyme location Mitochondria

Enzyme Function Production of adenosylcobalamin

Missing Enzyme Cobalamin A (cblA) deficiency: cobalamin reductase

Cobalamin B (cblB) deficiency: cobalamin adenosyltransferase

Metabolite changes Elevated glycine in urine

Prenatal testing Possible via enzyme assay on amniocytes or CVS..

MS/MS Profile Elevated C3 propionyl carnitine, elevated C4 DC methylmalonyl carnitine.

OMIM Link www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=251000

Genetests Link www.genetests.org

Support Group Organic Acidemia Association

www.oaanews.org

Save Babies through Screening Foundation

www.savebabies.org Genetic Alliance www.geneticalliance.org

Fatty Oxidation Disorder (FOD) Family Support Group

www.fodsupport.org

4-26-2010 Update

